At present, the Pharmaceutical Office of the Consumer Goods Industry Department of Ministry of Industry and Information Technology of the People’s Republic of China ranked national top 100 industrial enterprises in the pharmaceutical industry of 2009 based on the total assets value, the primary business operation income and the total profits respectively. YRPG all ranked in the top with its outstanding performance, in which it ranked on the top in terms of the primary business operation income, at the 7th place in terms of the total assets value, and at the 4th place in terms of the total profits. It has displayed its outstanding strength and sound development potentials.
YRPG was developed against the tendency in face of austere international and domestic economic environment in 2009 by increasing its sales and profit tax by 15% and 18% respectively than those of the same period in the preceding year. The group further boasted flourishing production and sales from January to April of this year and continued to march forward with the increase beyond 30%, a new record of the operation performance. In the future, the group would persist in development with innovation, accelerate to transform the development method, make innovations in R&D and sales, and strive to upgrade its core competitiveness so as to promote the enterprise’s development in a sound and rapid manner.